Diabetes mellitus is one of the main causes of death due to the complications that involve many organs such as heart, kidney, retina and others. Mesenchymal stem cells (MSCs) have been demonstrated to be effective in treatment of diabetes. This paper aims to evaluate the effect of stem cells in the treatment of diabetic nephropathy, clarifying their role in oxidative stress and inflammation. 30 adult male albino rats were equally divided into 3 groups. Control group (group I) received 1ml saline by intra-peritoneal (IP) injection. Streptozotocin-treated group (group II) received Streptozotocin (STZ) (60 mg/kg BW, I.P.) for induction of diabetes, then were sacrificed after 4 weeks. Steptozotocin + Stem cell-treated group (group III) received STZ, were left for 4 weeks, and then they were injected once intravenously with 1 million units of MSC and sacrificed after 4 weeks. Blood glucose, serum urea and creatinine were checked. The kidney sections were examined Histologically with H&E and PAS Stain and immunohistochemically for endothelial Nitric Oxide Synthase (eNOS). A morphometric study and statistical analysis were performed. DM led to increased levels of glucose, urea and creatine. Also, DM caused inflammation, degeneration and decreased eNOS immunoexpression of the kidney. The administration of MSCs improved the levels of glucose, urea and creatinine. Also, MSCs decreased the pathological changes and increased eNOS immunoexpression in the kidney. MSCs have effective therapeutic role in treating diabetic nephropathy.
Ahmed Y. Sedeak1, Hanan D. Yassa1, Azza S. Moawad3, Abdalwakel A. Mohammed2, Gaber H. Abdelfatah1
1 Anatomy and Embryology Department, Faculty of Medicine, Beni-Suef University, Egypt
2 Anatomy and Embryology Department, Faculty of Medicine, Cairo University, Egypt
3 Histology Department, Faculty of Medicine, Beni-Suef University, Egypt